首页 | 本学科首页   官方微博 | 高级检索  
     

乌灵胶囊联合黛力新治疗脑卒中后抑郁疗效和安全性的随机对照研究
引用本文:付剑亮,赵玉武,孙晓江. 乌灵胶囊联合黛力新治疗脑卒中后抑郁疗效和安全性的随机对照研究[J]. 中西医结合学报, 2008, 6(3): 258-261
作者姓名:付剑亮  赵玉武  孙晓江
作者单位:上海交通大学第六人民医院神经内科,上海,200233
摘    要:目的:观察乌灵胶囊联合黛力新治疗脑卒中后抑郁的临床疗效和安全性。方法:采用平行对照研究方法,将卒中后抑郁病人随机分为乌灵胶囊组(n=39),给予乌灵胶囊,每次3粒,3次/d;黛力新组(n=37),给予黛力新片,每次10.5mg.2次/d,早上、中午各服1次;联合组(n=38).在黛力新治疗基础上,加服乌灵胶囊。6周为1个疗程,于治疗前,治疗后2、4、6周用汉密顿抑郁量表(Hamilton Depression Scale,HAMD)评估疗效一治疗副反应量表(Treatment Emergent sympton Scale.TESS)评定药物的不良反应,并检测血常规、尿常规、肝肾功能及心电图等。结果:乌灵胶囊组、黛力新组、联合治疗组总有效率分别为64.1%、64.9%和89.5%,乌灵胶囊组和黛力新组两组疗效差异无统计学意义(P〉0.05),联合组疗效优于另两组(P〈0.05)。单纯应用乌灵胶囊组未见不良反应,应用黛力新的两组不良反应发生率均为9%。结论:乌灵胶囊联合黛力新治疗脑卒中后抑郁疗效优于单药治疗。

关 键 词:脑卒中  抗抑郁药  抑郁障碍  随机对照试验
文章编号:1672-1977(2008)03-0258-04

Efficacy and safety of Deanxit combined with Wuling Capsule in treating poststroke depression: A randomized controlled trial
Jian-liang FU,Yu-wu ZHAO,Xiao-jiang SUN. Efficacy and safety of Deanxit combined with Wuling Capsule in treating poststroke depression: A randomized controlled trial[J]. Journal of Chinese integrative medicine, 2008, 6(3): 258-261
Authors:Jian-liang FU  Yu-wu ZHAO  Xiao-jiang SUN
Affiliation:Department of Neurology, No.6 Hospital, Shanghai Jiaotong University, Shanghai 200233, China. fujianliang@163.com
Abstract:OBJECTIVE: To evaluate the safety and efficacy of Wuling Capsule combined with Deanxit in treating post-stroke depression (PSD). METHODS: One hundred and fourteen patients with PSD were randomly divided into Wuling Capsule-treated group (n=39), Deanxit-treated group (n=37) and Wuling Capsule plus Deanxit-treated group (n=38). Patients in Wuling Capsule-treated group were administered with three Wuling Capsules three times a day, and patients in Deanxit-treated group were administered with Deanxit 10.5 mg twice daily, while patients in the Wuling Capsule plus Deanxit-treated group were administered with both Wuling Capsule and Deanxit. Patients in the three groups were all treated for six weeks. Treatment efficacy was evaluated with Hamilton Depression Scale (HAMD) and the side effects were evaluated with Treatment Emergent Symptom Scale (TESS) before treatment and after 2-, 4-, and 6-week treatment. The blood and urine routine examinations were performed, and the hepatorenal functions and electrocardiogram were examined as well. RESULTS: There was no statistical difference in the total efficacy rate between Wuling Capsule-treated group and Deanxit-treated group (64.1% vs 64.9%, P>0.05), but the total efficacy rate of Wuling Capsule plus Deanxit-treated group was higher than that of the monotherapy (89.5% vs 64.1%, 89.5% vs 64.9%, P<0.05). There were no significant side effects in Wuling Capsule-treated group, while the incidence of side effects was 9% in both groups administered with Deanxit. CONCLUSION: The efficacy of Wuling Capsule plus Deanxit is better than that of the monotherapy in treating PSD.
Keywords:apoplexy  antidepressants  depressive disorder  randomized controlled trial
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号